{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Amplification", "query": { "condition": "HER2 Amplification" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Amplification&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T18:46:48.087Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03365882", "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "ERBB2 Gene Amplification", "Rectal Adenocarcinoma", "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage III Colon Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Colon Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Colon Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Colon Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Colon Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "HER-2 testing", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "DEVICE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2017-11-27", "completion_date": "2025-07-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 786, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03365882" }, { "nct_id": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "HR+/HER2- Breast Cancer", "HR+, HER2-, Advanced Breast Cancer", "CCNE1 Amplification", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "AVZO-021", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2023-08-30", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867251" }, { "nct_id": "NCT03630809", "title": "Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-positive Breast Cancer", "HER-2 Gene Amplification", "HER2 Positive Breast Carcinoma", "HER-2 Protein Overexpression", "Breast Cancer, Male", "Breast Cancer Female" ], "interventions": [ { "name": "HER2 DC1 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-01-10", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630809" }, { "nct_id": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2022-05-03", "completion_date": "2029-04-14", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 158, "location_summary": "Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Arcadia", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879329" }, { "nct_id": "NCT05315700", "title": "Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ORIC-114", "type": "DRUG" }, { "name": "Chemotherapy drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2022-03-10", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 17, "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05315700" }, { "nct_id": "NCT01613950", "title": "PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein" ], "interventions": [ { "name": "AUY922", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-12", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613950" }, { "nct_id": "NCT07288359", "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced HR+/HER2- Breast Cancer", "Advanced CCNE1-amplified Solid Tumors", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "GVV858", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2025-12-29", "completion_date": "2031-05-09", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 2, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288359" }, { "nct_id": "NCT03804515", "title": "A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "14C-labeled poziotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 2, "start_date": "2019-06-25", "completion_date": "2020-06-17", "has_results": false, "last_update_posted_date": "2021-06-15", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03804515" }, { "nct_id": "NCT00047255", "title": "Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "trastuxumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 263, "start_date": "2002-05", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047255" }, { "nct_id": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophageal Adenocarcinoma", "Metastasis", "HER-2 Gene Amplification" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5 fluorouracil", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ashwin Somasundaram", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-01-24", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-07-22T18:46:48.087Z", "location_count": 7, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03783936" } ] }